First Drug to Treat Alexander Disease Approved by FDA After 30 Years of Research
Summary
The FDA has approved Zanvastro, the first disease-modifying treatment for Alexander disease, a rare progressive neurological disorder that impairs motor, cognitive, and autonomic functions including heart rate and breathing. This landmark approval comes after three decades of research and represents a major breakthrough for patients who previously had access only to symptom management therapies. Alexander disease affects the brain's white matter and can be life-threatening without intervention. The availability of Zanvastro offers patients and their families hope for the first disease-modifying approach to slow or halt disease progression.
